Merck pips Novartis in MET race

Posted 21 January 2022 PM

Competition in the MET inhibitor space for non-small cell lung cancer (NSCLC) is heating up in Australia with Merck's Tepmetko finally provisionally approved this week as Novartis closes in with its candidate.

The TGA has granted Tepmetko provisional approval for the treatment of adult patients with locally advanced or metastatic NSCLC harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

To see the whole article, please login